Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study
- PMID: 20037169
- DOI: 10.1093/ndt/gfp679
Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study
Abstract
Background: Information on demographics and survival of patients starting renal replacement therapy (RRT) for end-stage renal disease (ESRD) due to multiple myeloma (MM) or light-chain deposit disease (LCDD) is scarce. The aim of this study was to describe the incidence, characteristics, causes of death and survival rates of RRT for ESRD due to MM or LCDD in the ERA-EDTA Registry.
Methods: Thirteen national registries providing data on patients who started RRT from 1986-2005 to the ERA-EDTA Registry participated. Incidence per million population (pmp) of RRT for ESRD due to MM or LCDD and other causes (non-MM) was observed overtime. Patient survival on RRT was examined, unadjusted and adjusted for age and gender.
Results: Of the 159 637 patients on RRT, 2453 (1.54%) had MM or LCDD. The incidence of RRT for ESRD due to MM or LCDD, adjusted for age and gender, increased from 0.70 pmp in 1986-1990 to 2.52 pmp in 2001-2005. MM and LCDD patients compared to non-MM patients were older and a higher percentage was on haemodialysis at day 91 after the start of RRT. The most common causes of death in MM and LCDD patients were malignancy (36.1%), cardiovascular causes (17.2%) and infection (14.7%). MM and LCDD patients had a 2.77 (95% CI, 2.65-2.90) higher risk of death compared to non-MM patients. The unadjusted median survival on RRT was 0.91 years in MM and LCDD patients and 4.46 years in non-MM patients. During follow-up, 35 patients were transplanted and their mean survival was 9.6 years.
Conclusion: The incidence of RRT for ESRD due to MM or LCDD has increased over the past 20 years in Europe. The median patient survival on RRT for MM and LCDD patients was 0.91 years, compared to 4.46 years for non-MM patients. These results suggest that dialysis, and in selected cases even transplantation, should be offered to MM and LCDD patients.
Comment in
-
Disease classification: a pitfall of the ERA/EDTA registry?Nephrol Dial Transplant. 2010 Aug;25(8):2799. doi: 10.1093/ndt/gfq290. Epub 2010 May 25. Nephrol Dial Transplant. 2010. PMID: 20501461 No abstract available.
Similar articles
-
An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006.Nephrol Dial Transplant. 2009 Dec;24(12):3557-66. doi: 10.1093/ndt/gfp519. Epub 2009 Oct 9. Nephrol Dial Transplant. 2009. PMID: 19820003
-
The 2006 ERA-EDTA Registry annual report: a précis.J Nephrol. 2009 Jan-Feb;22(1):1-12. J Nephrol. 2009. PMID: 19229813
-
Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival.Clin Nephrol. 2001 Sep;56(3):207-10. Clin Nephrol. 2001. PMID: 11597035
-
End-stage renal disease in the Asian-Pacific region.Semin Nephrol. 2003 Jan;23(1):107-14. doi: 10.1053/snep.2003.50009. Semin Nephrol. 2003. PMID: 12563605 Review.
-
[Survival of myeloma patients treated with dialysis].Nefrologia. 2003;23(2):131-6. Nefrologia. 2003. PMID: 12778877 Review. Spanish.
Cited by
-
Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney.Toxins (Basel). 2022 Jun 5;14(6):391. doi: 10.3390/toxins14060391. Toxins (Basel). 2022. PMID: 35737052 Free PMC article.
-
Acute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) project.J Oncol Pract. 2013 Mar;9(2):101-6. doi: 10.1200/JOP.2011.000486. J Oncol Pract. 2013. PMID: 23814519 Free PMC article.
-
Effect factors related to a high probability of hemodialysis independence in newly diagnosed multiple myeloma patients requiring hemodialysis.J Clin Lab Anal. 2020 Feb;34(2):e23057. doi: 10.1002/jcla.23057. Epub 2019 Oct 30. J Clin Lab Anal. 2020. PMID: 31663630 Free PMC article.
-
Galectin Plasmatic Levels Reveal a Cluster Associated with Disease Aggressiveness and Kidney Damage in Multiple Myeloma Patients.Int J Mol Sci. 2024 Dec 17;25(24):13499. doi: 10.3390/ijms252413499. Int J Mol Sci. 2024. PMID: 39769262 Free PMC article.
-
Kidney Injury in Multiple Myeloma: A Kidney Biopsy Teaching Case.Kidney Med. 2021 Feb 5;3(2):303-306. doi: 10.1016/j.xkme.2020.10.013. eCollection 2021 Mar-Apr. Kidney Med. 2021. PMID: 33851128 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous